摘要
目的探讨乳腺癌细胞中DNA拓扑异构酶Ⅱ（TopoⅡ）与c-erbB-2表达的相关性和临床意义。方法应用免疫组化S-P法检测TopoⅡ和c-erbB-2在220例乳腺浸润性导管癌组织中的表达。结果近一半乳腺浸润性导管癌病例不表达TopoⅡ蛋白,TopoⅡ和c-erbB-2的表达与乳腺浸润性导管癌的分级、淋巴结转移无明显相关性（P〉0.05）,TopoⅡ阳性率在c-erbB-2阴性病例中显著高于c-erbB-2阳性病例（P〈0.01）,在乳腺浸润性导管癌中TopoⅡ与c-erbB-2表达呈负相关。结论乳腺浸润性导管癌的多药耐药与TopoⅡ介导的耐药机制有关。检测乳腺浸润性导管癌组织TopoⅡ、c-erbB-2的表达可作为指导乳腺浸润性导管癌化疗的重要指标和判断乳腺浸润性导管癌预后的参考指标。
Objective To investigate the relationship between DNA topoisomerase Ⅱ （TopoⅡ ） and c-erbB-2 as well as its clinical significance in breast cancer. Methods The expression of Topo Ⅱ and c-erbB-2 were studied by immunohistochemical technique （S-P method）in 220 cases of breast invasive ductal carcinoma （None of the patients had received prior chemotherapy or radiotherapy）. Results Positive expression of Topo Ⅱ was shown in 126 of 220 cases breast invasive ductal carcinoma （57.27%）. Positive expression of c-erbB-2 was shown in 114 of 220 cases breast invasive ductal carcinoma （51.82%）. The level of Topo Ⅱand c-erbB-2 expression were not associated with histologic grade and lymph node metastases in breast invasive ductal carcinoma （P〈0.05）. Conclusion Expression of TopoⅡ and c-erbB-2 in carcinomatous tissue has an instructive significance for chemotherapy of breast invasive ductal carcinoma.
出处
《国际检验医学杂志》
CAS
2007年第7期600-601,共2页
International Journal of Laboratory Medicine
